MEND-CABG II: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG Surgery.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pyridoxal phosphate (Primary) ; Pyridoxal phosphate (Primary)
Indications Myocardial ischaemia; Myocardial reperfusion injury; Perioperative ischaemia
Focus Registrational; Therapeutic Use
Acronyms MEND-CABG-II
Sponsors Medicure

Most Recent Events

01 Apr 2008 Results published online (JAMA) and presented at ACC 2008
04 Mar 2008 Primary endpoint not met, as reported by Medicure in a media release.
15 Nov 2007 Status changed from in progress to completed.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight